aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
29 janv. 2025 08h00 HE
|
aTyr Pharma, Inc.
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
12 déc. 2024 16h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
10 déc. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
09 déc. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
15 nov. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
07 nov. 2024 16h01 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
aTyr Pharma to Present at Upcoming Investor Conferences
31 oct. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma to present at upcoming investor conferences
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
08 oct. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
02 oct. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal